Astrana Health, the West Covina-based population health management company formerly operating as Apollo Medical Holdings, enters the back half of 2026 with a business that is no longer recognizable from its origins as a fragmented IPA management operation. The rebrand, completed in 2024, accompanied a strategic pivot toward full-risk capitation, care enablement infrastructure, and a vertically integrated provider platform that now manages medical cost across hundreds of thousands of attributed lives in California and adjacent western markets. The second quarter results capture a company that has crossed an inflection point in both scale and operating leverage, with total revenue reaching $972.5 million, a 48.6 percent increase over the $654.8 million reported in the comparable prior-year quarter. That growth is not the product of a single acquisition or a one-time contract reshaping; it is the cumulative output of a multi-year build-out in risk-bearing primary care, a Care Enablement segment that monetizes administrative and clinical infrastructure for payors and self-insured employers, and a relentless expansion of attributed membership across Medicare Advantage, Medi-Cal managed care, and commercial ACO arrangements.
The first-half revenue figure of $1.94 billion, up from $1.28 billion in the first half of 2025, confirms that the quarterly acceleration is part of a sustained trajectory rather than a seasonal artifact. More telling is the profit progression: second-quarter net income of $18.5 million, nearly double the $10.2 million earned a year earlier, and first-half net income of $31.6 million against $16.4 million in the prior comparable period. The net income growth of roughly 93 percent in the second quarter meaningfully outpaces the revenue growth rate, a signal that Astrana is beginning to harvest operating leverage as fixed-cost administrative infrastructure spreads across a larger revenue base. The medical loss ratio discipline inherent in capitated contracts, combined with the company's proprietary care management platform, is producing margin expansion even as revenue scales rapidly.
What distinguishes Astrana from the broader population of value-based care operators is the structural composition of its revenue. A substantial majority of the top line derives from full-risk capitation arrangements under which the company receives fixed per-member-per-month payments and bears the medical cost risk for attributed populations. This contrasts sharply with fee-for-service medicine, where revenue is a function of volume and reimbursement rates, and with shared-savings ACO models, where upside is episodic and contingent on payor reconciliation cycles. Capitation creates a different economic engine: revenue is predictable and contracted, medical cost is the variable to be managed, and every basis point of medical cost ratio improvement flows directly to operating income. Astrana has invested years in building the data infrastructure, care coordination workflows, and provider network density to execute on that model in California, a state with the nation's largest Medicaid managed care program, a substantial Medicare Advantage market, and a regulatory environment that has historically favored organized physician groups willing to take downside risk.
The balance sheet supports the next phase of growth. Cash and cash equivalents of $400.8 million against total assets of $2.28 billion provide a liquidity cushion adequate to fund continued provider practice acquisitions, expand into adjacent geographies, and absorb the working capital demands of a growing capitated book. The company carries debt, but the asset base has expanded commensurately with the revenue base, and the cash position is more than sufficient to service near-term obligations and fund tuck-in M&A without requiring dilutive equity issuance. In a sector where many smaller value-based care operators are capital-constrained and dependent on payor advances or credit facilities to bridge medical cost timing, Astrana's self-funded liquidity is a structural advantage.
The Care Enablement segment is the less-understood component of the investment thesis. While the risk-bearing provider business generates the majority of revenue and most of the reported net income, Care Enablement monetizes the technology, analytics, and administrative platform that Astrana has built internally. This segment provides services to external payors, providers, and self-funded employer groups, generating fee-based revenue that carries higher incremental margins and requires less regulatory capital than the insurance-like risk business. As the platform matures and third-party demand for value-based care infrastructure grows, Care Enablement represents a leveraged revenue stream that can expand margins at the consolidated level while diversifying the earnings mix away from pure medical cost risk.
The competitive landscape in California value-based care is consolidating. Large payors have been vertically integrating with provider groups, and national risk-bearing platforms have been acquiring independent IPAs and medical groups. Astrana's scale, with approaching four billion dollars in annualized revenue run-rate and a multi-county provider network, positions it as a credible consolidator rather than a consolidation target. The company's track record of integrating acquired practices, retaining physicians, and improving medical cost ratios in acquired books gives it a credibility advantage with sellers that smaller, less-capitalized buyers cannot match. The M&A environment in California physician practice management remains fragmented at the sub-scale end, providing a long runway of tuck-in targets priced at reasonable multiples of EBITDA.
The investment question is not whether Astrana can grow, because the capitated membership base and Care Enablement pipeline answer that affirmatively. The question is whether the company can continue to hold medical cost ratios in a range that produces expanding operating margins as it absorbs new populations, particularly in Medi-Cal where rate adequacy and acuity have been volatile across the state. Management has demonstrated medical cost discipline through prior enrollment expansions and Medicaid redetermination cycles, but each new cohort of attributed lives carries its own acuity profile and utilization pattern. The second quarter results suggest the model is working as designed, with revenue growing faster than medical cost and operating expenses, producing the margin expansion that capitated business models are designed to deliver at scale.